Key Summary Points {#FPar1}
==================

**Why carry out this study?**  Prostaglandin analogue (PGA) and beta-receptor blocker combination therapies are among the most extensively used intraocular pressure (IOP)-lowering treatments in glaucoma care. Fixed-dose combinations simplify the treatment regimen and reduce the number of daily instillations, compared with administration of the corresponding concomitant medications, and preservative-free formulations are generally considered to offer improved tolerability.  The VISIONARY study aimed to provide real-world data concerning the treatment effectiveness of the preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in people with open-angle glaucoma (OAG) and ocular hypertension (OHT) who demonstrated an insufficient response to previous monotherapy treatment with topical beta-receptor blocker or PGA monotherapy.**What was learned from the study?**  Mean (SD) IOP reduction from baseline for patients switched to PF tafluprost/timolol FC from PGA or timolol therapy was 5.4 (3.76) mmHg (23.7%) at week 4, 5.9 (3.90) mmHg (25.6%) at week 12 and 5.7 (4.11) mmHg (24.9%) at month 6 (*p* \< 0.0001 for all visits).  In routine clinical practice, PF tafluprost/timolol FC provided statistically and clinically significant IOP reduction already at week 4, and the efficacy was maintained over 6 months in patients with OAG and OHT insufficiently controlled on PGAs or beta-receptor blockers.  Key symptoms of ocular surface health were improved, compared with previous PGA or beta-receptor blocker monotherapy, and treatment was generally well tolerated.

Introduction {#Sec1}
============

Elevated intraocular pressure (IOP) is the most important modifiable risk factor for development and progression of open-angle glaucoma (OAG) \[[@CR1]\]. A wealth of data has demonstrated that IOP reduction is associated with slowing of disease progression and visual field impairment; IOP reduction is thus essential for the preservation of vision in glaucoma \[[@CR1]--[@CR5]\].

Topical IOP-lowering medication remains the mainstay of glaucoma therapy \[[@CR1]--[@CR5]\]. Strong IOP-lowering efficacy, a simplified instillation regimen, and good topical and systemic tolerance are all essential for optimal treatment outcomes and long-term adherence with topical glaucoma medications \[[@CR6], [@CR7]\]. When monotherapies do not reach the target IOP, combination therapy is necessary \[[@CR6]\]. Prostaglandin analogue (PGA) and beta-receptor blocker (typically timolol 0.5%) combination therapies are among the most extensively used medications in glaucoma care \[[@CR6], [@CR8]\]. Fixed-dose combination (FC) formulations are frequently used in preference to the administration of the corresponding concomitant medications, since they simplify the treatment regimen and reduce the number of daily instillations as well as the total amount of preservatives applied to the eye \[[@CR1], [@CR6], [@CR7], [@CR9]--[@CR11]\].

Preservative-free (PF) topical glaucoma therapy has become increasingly used in the management of glaucoma worldwide \[[@CR7], [@CR10]--[@CR18]\]. Preservatives, and in particular benzalkonium chloride (BAK), the most commonly used preservative, have been shown to induce and seriously worsen ocular surface disease (OSD) \[[@CR7], [@CR19]--[@CR24]\]. Preservative-induced OSD is a major problem in the long-term topical treatment of glaucoma, affecting 45--60% of chronically treated glaucomatous eyes \[[@CR7], [@CR25], [@CR26]\]. PF medication is potentially advantageous for all glaucomatous eyes because the BAK-induced ocular surface toxicity worsens with the duration of preserved topical treatment \[[@CR7], [@CR19]--[@CR27]\]. The overall quantity of BAK used throughout a patient's lifetime is also inversely related to filtration surgery success \[[@CR7], [@CR19]--[@CR27]\]. The fixed combination of tafluprost 0.0015% and timolol 0.5% was one of the first PF PGA/timolol FCs used for the treatment of OAG and ocular hypertension (OHT) \[[@CR10], [@CR14]--[@CR18]\]. Randomized controlled trials demonstrated a low rate of conjunctival hyperemia with PF tafluprost/timolol FC treatment \[[@CR14], [@CR15]\]. A recent 24-h investigation also showed that PF tafluprost/timolol FC was associated with less frequent and less severe hyperemia compared with the pre-study period on preserved latanoprost treatment \[[@CR10]\].

Randomized, prospective, controlled investigations remain the gold standard for robust assessment of efficacy and safety data for regulatory purposes. However, as a result of their inclusion and exclusion criteria, the full spectrum of routine clinical practice cannot be explored in such investigations. Regarding topical glaucoma medications, observational studies may provide additional information on tolerance and real-life effectiveness since these investigations also report on patients with OSD or other relevant comorbidities that represent exclusion criteria in most randomized, prospective, clinical studies. In addition, observational studies reflect real-world experience concerning medication change without prior treatment washout. Therefore, real-world evidence is becoming increasingly welcomed by regulatory bodies \[[@CR28]--[@CR30]\].

In the current investigation, systematically registered clinical data were used to evaluate the IOP-lowering effectiveness and tolerability of the PF tafluprost/timolol FC over a 6-month period in participants with OAG and OHT, who were previously treated with either a topical PGA or a topical beta-receptor blocker monotherapy.

Methods {#Sec2}
=======

Study Design and Visit Schedule {#Sec3}
-------------------------------

This was a 6-month, observational, multicenter, European, prospective clinical study. In line with European Medicines Agency (EMA) requirements, the study was registered under the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP^®^) European Union electronic Register of Post-Authorisation Studies (EU PAS Register) (EU PAS register number EUPAS22204). The study complied with the principles of the Declaration of Helsinki. All patients included were required to provide written informed consent prior to their enrollment. The study protocol was approved by the institutional review board (IRB) or independent ethics committee (IEC) at each center/institution. The study centers/institutions are listed in the Acknowledgments alongside the relevant principal investigator.

Data were prospectively collected during routine visits, between 10 April 2017 and 9 January 2019, at 66 ophthalmology clinics in Austria, Denmark, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, Russia, Spain, Sweden, and the UK. For patients, attendance was mandatory only for the baseline and month 6 study visits. However, data were recorded during interim study visits at week 4 and week 12 for participants who chose to attend these visits.

Baseline measures were recorded under topical PGA or beta-receptor blocker medication within 7 days prior to therapy change to PF tafluprost/timolol FC. Variables were documented for each eye separately at baseline and at study visits following initiation of PF tafluprost/timolol FC treatment. Where data on both eyes were available, the eye with the higher baseline IOP value was selected for analysis (study eye).

Patient Population {#Sec4}
------------------

Male/female adult patients (aged ≥ 18 years) with a diagnosis of OAG or OHT were included in the study. Participants had to be on a PGA or a beta-receptor blocker monotherapy at time of inclusion. They had to have medically recorded insufficient IOP control or poor tolerance on the beta-receptor blocker or PGA monotherapy prior to enrollment, which necessitated the use of a combination therapy, and the patients had to be considered likely to benefit from PF drops formulation, according to the judgement of the investigator ophthalmologist. It was possible for the investigator to indicate more than one reason for patient selection in the case report form. The category of reasons for indicating PF tafluprost/timolol FC comprised insufficient IOP control or progression of glaucoma on the current monotherapy, conversion of OHT to OAG, poor local tolerance of the current topical medication, insufficient adherence to the medication used, or "other reasons".

The inclusion criteria required that the participants had not undergone ophthalmic surgery within 6 months prior to the study period and had never received previous PF tafluprost/timolol FC treatment. Patients who were pregnant or breastfeeding at the screening visit and those with any contraindication against tafluprost or timolol treatment according to the approved licensed indication and the summary of product characteristics were not allowed to enter the study.

Treatment {#Sec5}
---------

During the 6-month study period, the participants treated their affected eye(s) with PF tafluprost/timolol FC (one drop daily, instilled either in the morning or in the evening). The instillation time (morning or evening) was recorded at all study visits.

Efficacy Variables {#Sec6}
------------------

The primary endpoint was absolute mean IOP change from baseline at month 6, following the initiation of PF tafluprost/timolol FC treatment, measured with Goldmann applanation tonometry in accordance with routine clinical practice \[[@CR6]\]. Secondary endpoints comprised mean IOP change from baseline at interim visits, responder rate, change in clinical signs, and severity of subjective symptoms.

Responders were defined as patients with IOP change from baseline of 20% or more at week 12. In addition, the responder rate was also explored at week 4 and month 6. Other cutoff points for change in mean IOP that were explored at week 4, week 12, and month 6 comprised 25%, 30%, and 35%.

Subanalyses of IOP data comprised mean IOP change from baseline according to the diagnostic group (containing \> 10 patients), the type of previous medication (PGA or beta-receptor blocker), the PGA molecule (latanoprost, bimatoprost, travoprost, and tafluprost) for those using a PGA at baseline, the reported reasons for the PF tafluprost/timolol treatment initiation, instillation time (morning or evening), and the presence or absence of dry eye symptoms.

The clinical (ocular) signs were evaluated at month 6 and were compared with the baseline measures in all participants. Conjunctival hyperemia and best corrected visual acuity (BCVA) data reporting was mandatory at all study visits. Visual acuity data were collected in decimal, logMAR, or fraction (foot or meters) scales (according to the sites' practice) and were converted to the decimal scale using the appropriate conversion formulas \[[@CR31]\]. Data concerning corneal fluorescein staining (CFS) were reported using the Oxford grading scale (0--V grade dependent on intensity of punctate staining across the cornea and conjunctiva) \[[@CR32]\]. Schirmer's test, tear film breakup time (TBUT), and conjunctival hyperemia were collected at baseline and month 6; however, these evaluations were allowed as optional tests at interim visits. Conjunctival hyperemia was evaluated using a four-grade severity scale (none, mild, moderate, and severe).

The subjective symptoms were assessed at each study visit. These comprised dry eye feeling, irritation, itching, foreign body sensation, and eye pain. Symptom severity was evaluated using a four-grade scale (none, mild, moderate, and severe). In addition, the investigator provided evaluation concerning the effectiveness of the PF tafluprost/timolol FC therapy, the clinical signs, and compliance to the study medication compared with those for the prior monotherapy using a three-grade scale: better than prior medication, same as prior medication, worse than prior medication. Patients reported their assessment of tolerability concerning PF tafluprost/timolol FC treatment on a four-grade scale: very good, good, satisfactory, poor.

Reported adverse events (AEs) and treatment-related AEs were collected and documented at all visits and for the total study period.

Statistical Analysis {#Sec7}
--------------------

ICON Plc (Dublin, Ireland) conducted all statistical analyses on behalf of the VISIONARY study group. Data distribution was assessed using *Q*--*Q* plots, histograms, and the Shapiro--Wilk or the Kolmogorov--Smirnov test, as needed. For normally distributed data, the mean and standard deviation (SD) are presented and the paired *t* test was used for the comparisons. For data not normally distributed, the median values and the interquartile range (IQR) are shown and the Wilcoxon signed rank test was used to assess change in median from baseline. A linear mixed model was run with IOP as the dependent variable and all time points as independent variables to investigate time-dependent IOP changes. Time-independent comparisons between IOP values at each study visit and the baseline value utilized a paired *t* test, taking account of repeated measures. Change from baseline concerning CFS, conjunctival hyperemia, and subjective symptoms was assessed using the Bhapkar test. The Bhapkar test can be used in marginal homogeneity and it assumes that the changes are non-directional \[[@CR33]\].

Results {#Sec8}
=======

Study Population Demographics {#Sec9}
-----------------------------

In total, 721 participants were screened for inclusion in the study and 713 were treated with the PF tafluprost/timolol FC. Of these, 577 went on to complete the 6-month visit and were included in the analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Patient disposition

The baseline study population demographics are shown in Table [1](#Tab1){ref-type="table"}. Mean age (SD) was 67.8 (11.67) years (range 23.7--96.1 years), and 59.6% of the final population were female. The most common diagnostic groups comprised primary open-angle glaucoma (POAG; 73.7%), OHT (19.1%), pseudoexfoliative glaucoma (3.3%), and normal tension glaucoma (2.3%). The majority of the patients (72.1%) changed medication from a PGA and 27.9% from beta-receptor blocker (timolol) therapy. At baseline, the mean (SD) IOP was 21.55 (4.45) mmHg, the mean (SD) CFS score was 0.76 (0.94), and median BCVA decimal score (IQR) was 0.9 (0.4).Table 1Demographics of the participantsSex, *n* (%) Male233 (40.4) Female344 (59.6)Age (years) Mean ± SD67.8 ± 11.67 Range23.7--96.1Diagnosis, *n* (%) POAG425 (73.7) OHT110 (19.1) Pseudoexfoliative glaucoma19 (3.3) Normal tension glaucoma13 (2.3) Pigmentary glaucoma5 (0.9) Other glaucoma5 (0.9)Study eye, *n* (%) Right363 (62.9) Left214 (37.1)Previous treatment, *n* (%) Beta-blocker therapy161 (27.9) PGA therapy416 (72.1)IOP at baseline, mmHg (mean ± SD)21.55 ± 4.45CFS score (Oxford grade scale) (mean ± SD) (*n* = 238)0.76 ± 0.94BCVA decimal score, median (IQR) (*n* = 461)0.9 (0.40)Schirmer's test, median (IQR) (*n* = 124)10.0 (8.00)TBUT seconds, median (IQR) (*n* = 176)6.0 (5.00)*SD* standard deviation, *POAG* primary open-angle glaucoma, *OHT* ocular hypertension, *PGA* prostaglandin analogue, *IOP* intraocular pressure, *CFS* corneal fluorescein staining, *BCVA* best corrected visual acuity, *TBUT* tear breakup time, *IQR* interquartile range

IOP Change from Baseline {#Sec10}
------------------------

Concerning the primary endpoint, the absolute mean IOP change at month 6 was statistically significant (*p* \< 0.0001) (Table [2](#Tab2){ref-type="table"}). Mean (SD) IOP at month 6 was 15.8 mmHg (3.21). Mean (SD) IOP reduction from baseline was 5.7 (4.11) mmHg, representing an overall IOP reduction of 24.9%. Statistically significant mean IOP reductions from baseline were observed at each of the interim study visits. At week 4, it was 5.4 (3.76) mmHg (23.7%; *p* \< 0.0001), and 5.9 (3.90) mmHg (25.6%; *p* \< 0.0001) at week 12. At month 6, 69.2%, 53.6%, 40.0%, and 25.8% of participants were responders based on ≥ 20%, ≥ 25%, ≥ 30%, and ≥ 35% cutoff values for change in mean IOP, respectively (Fig. [2](#Fig2){ref-type="fig"}).Table 2Intraocular pressure change from baseline at week 4, week 12, and month 6Visit*N*Mean (SD) IOP (mmHg)Mean (SD) reduction in IOP from baseline (mmHg)Mean percentage reduction in IOP from baseline*p* value^\#^Baseline57721.5 (4.45)Week 454116.2 (3.28)5.4 (3.76)23.7\< 0.0001Week 1250315.7 (3.98)5.9 (3.90)25.6\< 0.0001Month 657715.8 (3.21)5.7 (4.11)24.9\< 0.0001*IOP* intraocular pressure^\#^Significance testing using two-sided paired*t* test for change in mean IOP from baseline to week 4, week 12, and month 6Fig. 2Percentage of responders according to different intraocular pressure reduction cutoff values at month 6. IOP intraocular pressure

### Intraocular Pressure Subanalyses {#Sec11}

The mean (SD) IOP at baseline was 21.5 (5.00) mmHg, 22.3 (4.30) mmHg, 17.2 (2.68) mmHg, and 21.7 (4.13) mmHg for patients diagnosed with POAG, OHT, normal tension glaucoma, and pseudoexfoliative glaucoma, respectively. At month 6, respective relative IOP reductions were 25.4%, 26.1%, 15.8%, and 17.6%. Differences between subgroups did not reach statistical significance (*p* ≥ 0.324).

At baseline, mean (SD) IOP was 21.9 (4.36) mmHg and 21.4 (4.48) mmHg for the beta-receptor blocker and PGA users, respectively. At month 6 IOP was 15.3 (3.10) mmHg in those previously using a beta-receptor blocker, representing 6.6 (4.16) mmHg (28.5%) reduction from baseline (*p* \< 0.0001). In those treated with a PGA, at month 6 IOP was 16.0 (3.23) mmHg, representing 5.4 (4.04) mmHg (23.6%) reduction (*p* \< 0.0001).

Prior to the study period, 64, 63, 87, and 201 patients were on bimatoprost, travoprost, tafluprost, and latanoprost, respectively (for one patient in the study population, the specific PGA used was not recorded). The IOP at baseline was 20.6 (4.39) mmHg, 20.0 (3.90) mmHg, 20.8 (3.29) mmHg, and 22.3 (4.93) mmHg for participants treated with bimatoprost, travoprost, tafluprost, and latanoprost, respectively. At month 6, respective mean relative IOP reductions were 20.5%, 21.3%, 22.7%, and 25.9% (*p* \< 0.0001 for all groups).

Of the 577 participants included in the analysis, 469 individuals (81.3%) changed to PF tafluprost/timolol FC treatment because of uncontrolled IOP, and 106 (18.4%) were enrolled because of poor ocular tolerance on the previous topical IOP-lowering medication (irrespective of the success of the IOP control). At month 6, the mean relative IOP reduction was 26.6% for participants with insufficient IOP control at baseline and 19.6% for those who did not tolerate the previous topical medication well (*p* \< 0.001).

At month 6, the instillation time (morning versus evening) was recorded for 521 patients. The mean (SD) relative IOP reduction from baseline was 5.50 (4.14) mmHg (23.6%) for those using morning instillation and 5.67 (3.99) mmHg (24.7%) for evening instillation (*p* = 0.5966). The mean relative IOP reduction was not significantly different when comparing those who reported no dry eye symptom at baseline (*n* = 242) and those (*n* = 224) who reported any severity of dry eye symptom (24.9% vs 24.4% at month 6, *p* = 0.754).

Clinical Signs {#Sec12}
--------------

Compared with the baseline value, the mean (SD) CFS score was reduced at all study visits during the PF tafluprost/timolol FC treatment (Table [3](#Tab3){ref-type="table"}). At baseline, the median (IQR) Schirmer's test result was 10.0 (8.0). No statistically significant change was seen concerning the Schirmer's test result during the study period (*p* = 0.258). TBUT was 6.0 (5.0) s at baseline and increased by an average 1 s value at all later study visits (*p* = 0.0035). Statistically significant increases in median TBUT were observed at each study visit for participants on baseline PGA monotherapy (*p* = 0.0012) but not in beta-receptor blocker users (*p* = 0.7490).Table 3Cornea fluorescein staining score and its change during the study periodMean change from baseline*N*Mean (SD)*N*Mean (SD)*p* value\*Baseline2340.76 (0.94)Week 4 (± 7 days)2430.55 (0.76)2020.19 (0.75)^1^0.0003Week 12 (± 7 days)2260.54 (0.78)1890.21 (0.93)^2^0.0020Month 6 (± 45 days)2720.47 (0.71)2200.27 (0.95)^3^\< 0.0001Change in median CFS at baseline and respective time point along with Wilcoxon signed rank test *p* value were ^1^*p* = 0.0003; ^2^*p* = 0.0023; ^3^*p* \< 0.0001*CFS* corneal fluorescein staining

CFS scores of 0 or 1 were found in 188 (80.3%) patients at baseline and in 249 (91.5%) at month 6 among those with data available. The mean (SD) CFS score at month 6 was 0.47 (0.71), which was a statistically significant reduction compared with the mean baseline value (0.76 \[0.94\]; *p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}). Overall, 32.7% of patients demonstrated a reduction in the CFS score from baseline at month 6, 53.6% showed no change, and CFS was increased in 13.6% of the patients.

Statistically significant reductions, compared with baseline values, were found for conjunctival hyperemia at week 4, week 12 and month 6 (*p* \< 0.0001 for each study visit). At month 6, 38.7% of the patients demonstrated reduction in conjunctival hyperemia, 50.7% showed no change, and 10.7% showed increased hyperemia. At baseline, conjunctival hyperemia was mild or absent in 79.6% of participants on latanoprost, 88.9% of those treated with tafluprost, 60.4% on bimatoprost, and 66.7% on travoprost (Fig. [3](#Fig3){ref-type="fig"}). Moderate or severe hyperemia was reported for the remaining patients at baseline. During the study period, conjunctival hyperemia was significantly reduced at all study visits for participants treated with each of the baseline PGA monotherapies; latanoprost (*p* \< 0.0001), tafluprost (*p* = 0.029), bimatoprost (*p* \< 0.0001), and travoprost (*p* \< 0.0001). The greatest improvement in conjunctival hyperemia severity was found in participants previously treated with bimatoprost or travoprost (\> 59.6% improvement at each study visit, for both medications).Fig. 3Change in conjunctival hyperemia severity according to the previous prostaglandin analogue treatment. Severity of conjunctival hyperemia at each study visit for those previously treated with **a** latanoprost, **b** tafluprost, **c** bimatoprost, or **d** travoprost

Subjective Symptoms {#Sec13}
-------------------

At baseline, subjective symptoms were generally reported absent or of mild severity. This was the case for more than 80% of patients concerning dry eye, irritation, and itching, and more than 90% for individuals reporting of foreign body sensation and eye pain. However, at month 6, statistically significant reductions from baseline were reported concerning severity of dry eye, irritation, itching, and foreign body sensation (*p* \< 0.001 for each category). Overall, dry eye severity was reduced for 30.8% of the patients, while 59.3% of the participants reported no change, and 9.8% of the patients reported increased severity. Severity of irritation was reduced in 31.0% of the participants, while 61.0% experienced no change. Itching severity was reduced in 26.6% of participants, while 62.8% reported no change. Foreign body sensation was reduced in 23.0% of the participants, 69.9% reported no change, and an increase in severity was reported by 7.5% of the patients. No significant change was found concerning eye pain severity at month 6 (*p* = 0.058); 7.8% of the participants reported pain reduction, 88.9% experienced no change, and 3.3% reported that the pain increased.

Physician Assessments {#Sec14}
---------------------

On the basis of clinical evaluation, most investigators (84.7%) considered IOP control more effective with PF tafluprost/timolol FC treatment than with the previous medication, at month 6. The investigators also reported reduced ocular signs at month 6 in 63.6% of the participants, compared with the previous medication. Overall, compliance to the PF tafluprost/timolol FC treatment was perceived to be greater (48.9%) or comparable (46.0%) with that on the previous medications, when evaluated by the investigators.

Patient Assessment {#Sec15}
------------------

The majority of patients reported that the tolerability of the PF tafluprost/timolol FC treatment was good or very good at week 4 (87.9%), week 12 (92.4%), and month 6 (91.4%).

Reasons for Discontinuation {#Sec16}
---------------------------

Overall, 98 patients (17.0%) discontinued the PF tafluprost/timolol FC treatment during the 6-month study period. The reported reasons of treatment discontinuation comprised insufficient IOP control for 2 patients, poor local tolerance for 12 patients, poor compliance for 4 patients, and "other reasons" for 13 patients. Data were missing for the remaining 67 patients.

Safety {#Sec17}
------

For the 577 individuals included in the safety analysis, 129 AEs were reported by 99 (17.2%) patients during the 6-month study period. The majority of the AEs (94.6%) were reported as non-serious, and 69 (53.5%) were considered to be treatment-related (Table [4](#Tab4){ref-type="table"}). One of these was serious (status asthmaticus). Most AEs (93.0%) were mild to moderate in severity, and the majority (71.3%) had resolved or were resolving at the point of data cutoff.Table 4Treatment related adverse events reported during the study periodSystem/organ classNumber of treatment-related AEsOcular disorders Blepharal pigmentation2 Blepharitis1 Conjunctival hyperemia1 Ocular hyperemia4 Conjunctivitis2 Eye pain23 Eyelid erythema1 Eyelid edema1 Eye Pruritis2 Dry eye1 Keratitis2 Foreign body sensation2 Eyelash growth1 Blurred vision1 Eye discharge1 Ocular irritation1 Iris hyperpigmentation1 Lacrimation increased1 Ocular discomfort2Respiratory Asthma1 Status asthmaticus1Neurological Headache1 Dizziness3Cardiovascular Palpitations1 Atrioventricular block1 Bradycardia1Dermatological Skin hyperpigmentation1 Abnormal hair growth1 Rash1Immune disorders Hypersensitivity/allergy4General disorders Fatigue2 Chest pain1Total69

Discussion {#Sec18}
==========

In the current 6-month, observational, multicenter, European, prospective clinical investigation completed by 577 patients with OAG and OHT, clinical experience with changing topical medication from a PGA or a beta-receptor blocker to the PF tafluprost/timolol FC was analyzed for IOP change, objective clinical ocular surface signs, the participants' subjective symptoms, and patient- and ophthalmologist-indicated satisfaction with the study medication. In this real-world study, no washout period between the prior and study medication was used, even when the prior medication was not optimally tolerated and patients with ocular surface abnormalities were included. Thus, in contrast to the randomized clinical trials previously conducted on the PF tafluprost/timolol FC, in which a complete washout period was used and the patients had to be free from ocular surface abnormalities, in the current investigation we mirrored real-life clinical practice, which is particularly important to all ophthalmologists \[[@CR10], [@CR14]--[@CR16]\].

Regarding IOP, we found a statistically and clinically significant, consistent IOP reduction at all time points including the week 4 and 12 visits, and at month 6, which was the primary endpoint of the investigation. At month 6, for the total population, the mean IOP reduction compared to the under-treatment baseline value was 5.7 mmHg (24.9%). Considering that the mean baseline IOP was 21.55 mmHg, this almost 25% IOP reduction is favorable since IOP reduction achieved with any PGA/timolol FC strongly depends on the baseline IOP, which was relatively low in our population \[[@CR34]\]. The mean IOP reductions found in the week 4 and week 12 visits were similar, which suggests that ophthalmologists can expect a meaningful IOP reduction shortly after the change to the tafluprost/timolol FC from a PGA or beta-receptor blocker monotherapy. Furthermore, the responder rates were also favorable. At month 6, almost 70% of the patients had an IOP reduction over 20%, and 53.6% and 40.0% of the patients experienced an IOP reduction over 25% and 30%, respectively. In almost 26% of the participants the relative IOP reduction exceeded 35%. These results suggest that there is high probability of reaching a clinically satisfactory IOP reduction with changing PGA or beta-receptor blocker medication for the PF tafluprost/timolol FC in OAG and OHT.

It is also of clinical importance that meaningful IOP reduction was achieved both in OHT and all types of glaucoma represented in the investigation (POAG, pseudoexfoliative glaucoma, and normal tension glaucoma). For all these groups the relative IOP reduction ranged between 17.6% (normal tension glaucoma) and 25.4% (POAG) with no statistically significant difference between the IOP reductions in the various disease categories. Another clinically important point is that the IOP reduction in previous beta-receptor blocker users (28.5%) was somewhat greater than that in previous PGA users (23.6%), even if their baseline under-treatment IOP was similar (21.4 and 21.9 mmHg, respectively). A similar IOP reduction was found for all PGAs used before the study (20.5--25.9%). This suggests that patients on all currently available PGA monotherapies benefit from changing to tafluprost/timolol FC, in terms of IOP reduction. Not unexpectedly, we found that those patients who were enrolled in the investigation because of insufficient IOP control on the previous monotherapy showed significantly greater IOP reduction than those participants who entered the study for poor tolerance of the previous medication (26.6% vs. 19.6%). At the same time, however, this finding also shows that even those patients who are considered as being controlled for IOP with a PGA or a beta-receptor blocker monotherapy can gain an almost 20% further IOP reduction by changing to the PF tafluprost/timolol FC. The similarity of IOP reduction of participants with or without dry eye symptoms at baseline (24.9% and 24.4% at month 6) also supports that the PF tafluprost/timolol FC cannot be considered as a glaucoma medication restricted only for dry eye or OSD patients. Finally, another important result of our study is that there was no difference in mean IOP reduction between those who instilled the tafluprost/timolol FC in the morning and those who instilled it in the evening (5.50 vs. 5.67 mmHg). This finding is of clinical importance since it shows that, in contrast to the controlled clinical investigations in which evening instillation of tafluprost/timolol FC provided somewhat lower diurnal IOP, in real-life conditions ophthalmologists can accept their patients' preference on the instillation time \[[@CR10]\]. This may support adherence and does not considerably influence the achieved IOP reduction.

Regarding ocular signs and symptoms, the change to PF tafluprost/timolol FC resulted in improvement in most of the measures used in our study. At month 6, the mean CFS score decreased significantly for the total study population. Almost one-third of the patients experienced a reduced CFS score. For the previous PGA users, the CFS score decreased significantly in all visits, compared to the baseline value. For the total population the mean conjunctival hyperemia score decreased significantly in all visits compared to the baseline score, and an improvement was seen in 38.7% of the patients in the month 6 visit. In the previous PGA users a highly significant reduction of hyperemia score was found for each of the four PGAs. The largest improvements were seen for the previous bimatoprost and travoprost users.

In all but one of the subjective symptom categories examined (dry eye feeling, irritation, itching, and foreign body sensation) a statistically and clinically significant improvement was reported at month 6; an improvement was found in 31.0% of the patients for dry eye feeling, 26.6% for eye itching, and 23.0% for foreign body sensation. No change in the eye pain score was found. These results show that many patients with glaucoma experienced considerable improvement of ocular tolerance on the PF tafluprost/timolol FC, even if their ocular surface-related complaints were mild or not obvious at baseline.

The evaluation of the study medication was positive by both the treating ophthalmologists and the study participants. At month 6, ophthalmologists considered IOP as better controlled with the PF tafluprost/timolol FC medication than with the previous monotherapy in 84.7% and classified the ocular signs as reduced compared to the baseline in 63.6%. They also considered compliance to the study medication better than to the previous monotherapy in almost half of the patients, while they indicated that the compliance was similar to that on the pre-study eye drop for 46.0% of the participants. The patient-reported tolerability was similarly favorable: the frequency of good or very good tolerability category ranged between 87.9% and 92.4% in all study visits.

Early termination was recorded in 98 patients (17.0%). As a result of the observational nature of the investigation the reason for study discontinuation was not clarified for 67 patients. The known reasons for study discontinuation were related to insufficient IOP control (2 patients), poor ocular tolerance (12 patients), and poor compliance (4 patients). Thirteen patients withdrew from the study for "other reasons". Of the 129 AEs reported by 99 patients, 69 were considered as treatment-related. Ninety-three percent of the AEs were mild and 73.1% had recovered or were recovering when the study was completed. Only one serious AE (status asthmaticus) was recorded, which probably could have been prevented by considering the contraindications of timolol, the beta-receptor blocker part of the study medication. The above safety data show that in general PF tafluprost/timolol FC was well tolerated.

Our study has limitations. It was an observational study; therefore, relatively many participants left the study without letting the investigators know about the reason for their early termination. The participants represented various areas of Europe, but their ethnicity was not investigated. Therefore, caution is needed when conclusions from our data are applied to patients with non-European origin. Since we investigated adult patients with OAG and OHT our results cannot be applied to angle-closure glaucoma and childhood glaucomas. We did not investigate switching to PF tafluprost/timolol FC from combined topical medication; therefore, our IOP results may not be reproduced when patients are switched from a fixed or unfixed topical combined medication regimen to PF tafluprost/timolol FC.

Conclusion {#Sec19}
==========

In our large multicenter observational study PF tafluprost/timolol FC demonstrated statistically and clinically significant IOP reductions in patients with OAG and OHT who were either insufficiently controlled on a PGA or beta-receptor blocker monotherapy, or did not tolerate these medications. The full IOP reduction was present already at the week 4 visit, and the efficacy was maintained over the total 6-month study period. The severity of most clinical signs and subjective symptoms decreased significantly compared to that on the previous treatment, and in general the PF tafluprost/timolol FC was well tolerated.
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